SuperworthNatures Sunshine Products EPS NATR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $1.01
- Latest quarter, Q2 FY26
- $0.19
- −32% on a year earlier
- Fiscal year 2025
- $1.06
- +165% on the year before
Natures Sunshine Products' earnings per share was $1.01 over the twelve months to Jun 30, 2026, up 36% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.19, down 32% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 0% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.06 | +165% |
| FY2024 | $0.40 | −48% |
| FY2023 | $0.77 | n/a |
| FY2022 | −$0.02 | −101% |
| FY2021 | $1.42 | +33% |
| FY2020 | $1.07 | +206% |
| FY2019 | $0.35 | n/a |
| FY2018 | −$0.04 | n/a |
| FY2017 | −$0.69 | −675% |
| FY2016 | $0.12 | −84% |
| FY2015 | $0.76 | +19% |
| FY2014 | $0.64 | −41% |
| FY2013 | $1.08 | −33% |
| FY2012 | $1.60 | +42% |
| FY2011 | $1.13 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.19 | −32% | $1.01 | |
| Q1 FY26 | $0.29 | +16% | $1.10 | |
| Q4 FY25 | $0.23 | n/a | $1.06 | |
| Q3 FY25 | $0.30 | +30% | $0.81 | |
| Q2 FY25 | $0.28 | +300% | $0.74 | |
| Q1 FY25 | $0.25 | +108% | $0.53 | |
| Q4 FY24 | −$0.02 | −104% | $0.40 | |
| Q3 FY24 | $0.23 | +53% | $0.88 | |
| Q2 FY24 | $0.07 | −42% | $0.80 | |
| Q1 FY24 | $0.12 | +200% | $0.85 | |
| Q4 FY23 | $0.46 | +360% | $0.77 | |
| Q3 FY23 | $0.15 | n/a | $0.41 |
Against its peers
Companies in Drug Manufacturers - General nearest Natures Sunshine Products' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| Peer median | $0.65 |
Where Natures Sunshine Products ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Natures Sunshine Products
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.